The tumor microenvironment plays an essential role in supporting glioma stemness and radioresistance; however, little is known about how the microenvironment responds to radiation. Here, we found that astrocytes, when pre-irradiated, increased stemness and survival of co-cultured glioma cells. Tumor-naïve brains increased reactive astrocytes in response to radiation, and mice subjected to radiation prior to implantation of glioma cells developed more aggressive tumors. We identified extracellular matrix derived from irradiated astrocytes as a major driver of this phenotype, and astrocyte-derived transglutaminase 2 (TGM2) as a promoter of glioma stemness and radioresistance. TGM2 inhibitors abrogated glioma stemness induced by irradiated astrocytes. TGM2 inhibition reduced survival of glioma cells in in vitro and ex vivo tumor models.
Introduction
Glioblastoma multiforme (GBM) is the highest grade glioma, with less than a 10% five year survival rate. 1 GBM is typically treated by surgical resection, followed by radiation and chemotherapy, yet nearly all tumors recur after treatment. 2 Tumors which recur generally form within or overlapping the original tumor volume 3 and within the initial field receiving high-dose radiation, suggesting that the recurring tumor forms within the irradiated brain microenvironment.
The recurred tumors have limited treatment options, and the mechanisms underlying therapeutic resistance are incompletely understood.
Recurrence of GBM is often attributed to radioresistant glioma cells. The radioresistant tumor cell phenotype appears to be closely related to the concept of tumor stemness, in that tumor cells surviving radiotherapy display several characteristics of stem cells, such as enhanced self-renewal and increased drug efflux capabilities, as compared to sensitive tumor cells. 4, 5 Understanding which factors promote stemness and treatment resistance of glioma cells is of intense interest in developing new therapies in glioma. A large number of studies over the past decade have established that there is considerable plasticity in glioblastoma cell phenotypes, [6] [7] [8] [9] [10] [11] that stem cell characteristics can be acquired by non-stem-like cells, 8, 9, [12] [13] [14] [15] and that microenvironmental cues such as hypoxia, 16 extracellular matrix proteins, [17] [18] [19] [20] [21] [22] [23] [24] [25] or growth factors secreted by stromal cells [26] [27] [28] may be sufficient to induce tumor cell stemness and therapeutic resistance. The role of the microenvironment in regulating tumor stemness is further supported by the finding that stem-like tumor cells are enriched in specific tumor niches; in GBM, primarily the perivascular niche (PVN) and hypoxic compartments. 16, 29, 30 The variety of stromal cell types found in the GBM microenvironment include cells associated with the PVN and hypoxic compartments, such as astrocytes, microglia, endothelial cells, and pericytes. 31 Several of these cell types have been shown to actively contribute to glioma aggressiveness. 32, 33 Little is known about how these cells respond to radiotherapy, and how they in turn might affect the associated glioma cells after irradiation. We sought to determine whether irradiation of the brain tumor microenvironment might affect the phenotype and therapeutic response of glioma cells. We identified astrocyte-derived transglutaminase 2 as a potential radiation-induced modifier of the tumor microenvironment, which protected against radiationinduced glioma cell death, and may thus serve as a potential therapeutic target in GBM.
Results

Irradiated astrocytes promote glioma cell stemness
We devised a co-culture scheme with which we could rapidly test a variety of control or irradiated stromal cells for their ability to increase one of the indicators of stemness in glioma cells, the side population (SP). [34] [35] [36] [37] To do this, we pre-irradiated four stromal cell types before co-culturing with non-irradiated PDGFB-induced glioma primary cells (PIGPC) derived from RCAS-PDGFBinduced gliomas in Nestin-tv-a Ink4a/Arf -/mice. Non-irradiated PIGPC were added to the preirradiated cells for co-culture for 48 h, followed by an SP assay. The experimental design for this screening is outlined in Figure 1A .
We pre-treated mouse brain endothelial cells (BEND3; Fig 1B) , human microglia (HMC3; Fig   1C) , primary human brain vascular pericytes (HBVP; Fig 1D) , and primary human astrocytes ( Fig   1E) with either 0 Gy or 10 Gy radiation, which is a therapeutic radiation dose in our tumor models.
PIGPC were used as control, non-stromal cells in each experiment to determine if co-culture with irradiated tumor cells alone could promote stemness features and to control for cell density. Only co-culture with pre-irradiated astrocytes stimulated a marked and consistent increase in SP of the PIGPC cells ( Fig 1E) . This suggests that irradiated astrocytes support glioma cell stemness.
To rule out that the stromal cells alone might contribute to the SP, we measured the SP of all the cell types before and after irradiation. Neither BEND3, HBVP, HMC3, nor astrocytes alone had a consistent SP before irradiation (Supplemental Fig 1) . Irradiation did not produce an SP of these stromal cells except in the case of HMC3, in which an erratic increase in SP was detected, which did not result in a statistically significant difference from non-irradiated cells (Supplemental Fig   1) . Co-culture of PIGPC with irradiated PIGPC also did not result in a significant increase in SP in any of the co-culture assays ( Fig 1B-E) .
Finding that tumor-naïve astrocytes irradiated in culture can promote the SP of glioma cells, we sought to determine whether astrocytes in the tumor-naïve brain might show increases in activation in response to irradiation. We stained brains from mice treated with 0 Gy or 10 Gy of radiation for GFAP, one of the markers of activation, and identified a trend of increased GFAP in the brains of mice treated with radiation ( Fig 1F-H) . This is consistent with previous findings from Chiang et al, 38 who showed increased GFAP expression 120-180 days post irradiation with 25-40 Gy dose of radiation. 38, 39 The irradiated brain microenvironment supports tumor growth After finding that pre-irradiated astrocytes could promote stemness features of glioma cells, we sought to determine whether radiation-induced changes in the brain microenvironment influence tumor growth or development. We therefore pre-irradiated mice with either 0 Gy or 10 Gy radiation to the brain, followed by intracranial injection with PIGPC 72 h post-radiation. Mice were sacrificed upon development of brain tumor symptoms (Fig 2A) . Mice which were preirradiated developed tumors with increased microvascular proliferation ( Fig 2B-D) and increased Ki67 positive nuclei ( Fig 2E-F) , both indicators of more aggressive, high grade glioma. Astrocytes were abundant within the tumor and associated with sites of microvascular proliferation ( Fig 2G) , one well established site enriched with stem-like glioma cells. 29 These findings suggest that irradiation of the brain microenvironment supports tumor growth and that astrocytes may play a role in this process.
Irradiated astrocytes produce a modified extracellular matrix which supports glioma cell stemness and radiation resistance
Co-culture of astrocytes with glioma cells may increase the glioma cell SP through direct cell-cell contact, secretion of soluble factors, or through modification of the extracellular matrix (ECM).
We devised two assays to isolate the effects of soluble factors and ECM components from irradiated astrocytes on glioma cells ( Fig 3A) . To determine whether pre-irradiated astrocytes stimulated increased SP of PIGPC via soluble factors, we suspended astrocytes in sodium alginate beads followed by treatment with either 0 Gy or 10 Gy irradiation. We then co-cultured these suspended astrocytes with PIGPC adhered to culture dishes, allowing the astrocytes to secrete cytokines into the media without direct cell-cell contact with PIGPC. We did not detect an increase in SP of PIGPC cells cultured in conditioned media from pre-irradiated astrocytes suspended in alginate beads (Supplemental Figure 2 ). This suggested the possibility of insoluble factors influencing the SP of the PIGPC cells. We therefore tested the potential of matrix proteins to affect the SP of PIGPC cells.
To generate purified ECM from astrocytes, confluent astrocytes were treated with either 0 Gy or 10 Gy radiation, then cultured for 10 days. The plates were de-cellularized, leaving behind insoluble matrix proteins (astrocyte derived matrix, ADM). Glioma cells were cultured on matrix from either 10 Gy-irradiated astrocytes (ADMi) or control, 0 Gy-treated astrocytes (ADMc) to examine the influence of ADM in various assays measuring stemness and radiation resistance ( Fig   3A) . Those assays include SP, self-renewal, and survival after irradiation.
Both PIGPC ( Fig 3B) and the serum-free cultured human glioma cell line U3082 ( Fig 3C) showed increased SP when cultured on ADMi. This suggests that changes in astrocyte derived matrix proteins after irradiation may be responsible for the increased SP of glioma cells co-cultured with irradiated astrocytes ( Fig 1E) . Another important measure of stemness is self-renewal capabilities, which can be measured by sphere formation capacity of clonal densities of glioma cells. To determine whether ADMi affected self-renewal, U3082 cells were conditioned by culturing for 5 days on ADMc or ADMi, followed by plating at clonal densities in 6-well dishes. After initial sphere formation, the spheres were disrupted and single cells were replated at clonal densities.
There were no changes in formation of primary spheres ( Fig 3D) , however quantification of secondary spheres revealed increased sphere formation of cells cultured on ADMi compared to ADMc ( Fig 3D) . Combined, the increase in SP and self-renewal of glioma cells cultured on ADMi compared to those cultured on ADMc suggests that astrocytes modify the ECM after irradiation to support glioma cell stemness.
To determine whether ADMi promotes radiation resistance of glioma cells, we plated clonal densities of human glioma U251 cells on ADMc or ADMi, followed by irradiation at 4 Gy, a dose that reduced colony formation by approximately 50% (Fig 3E) . Glioma cells cultured on ADMi showed increased colony formation after irradiation compared to cells cultured on ADMc ( Fig   3E) . This suggests that matrix from irradiated astrocytes has the capacity to promote radiation resistance of glioma cells.
RNA sequencing of U3082 cells cultured on ADMc or ADMi for 48 h revealed that culture on ADMi indeed resulted in global gene expression changes of glioma cells. Among gene sets significantly upregulated after culture on ADMi were pathways associated with the extracellular matrix, basement membrane, and integrin signaling ( Fig 3F) . Notable gene sets among the downregulated ones were associated with translation initiation and oxidative phosphorylation ( Fig   3F) .
Taken together, these data suggest that astrocytes modify matrix proteins after irradiation in a manner which promotes stemness, including radiation resistance of glioma cells.
Irradiation induces a reactive astrocyte phenotype which persists within the original tumor volume after irradiation
Astrocytes are an abundant cell type in the brain and in gliomas and are likely to survive radiotherapy. 40 It is well established that astrocytes respond to damage to the brain, 41 including radiation, 38, 39 and that this response typically involves a process termed reactive gliosis. This response varies across regions of the brain and damage type; however some phenotypes are shared amongst most reactive astrocytes, 41 such as GFAP upregulation and morphological reorganization, two hallmarks of reactive gliosis. 41 To understand the response of astrocytes to radiation in our models, we examined astrocytes after a 10 Gy dose of radiation in normal and tumor-bearing brains as well as purified, primary human astrocytes. Tumors were generated in Nestin-tv-a Ink4a/Arf -/mice by injection with RCAS-PDGFB and were irradiated upon symptoms of brain tumor with either 0 Gy or 10 Gy, then sacrificed 72 h later ( Fig 4A) . Whole brain sections were stained for Olig2 (green), which marks glioma cells, and GFAP (red), which marks activated astrocytes ( Fig 4B-C) . In 0 Gy-treated tumor-bearing brains, reactive astrocytes are enriched at the tumor borders and are found throughout the tumor itself, as can be seen in scans of the whole brain sections in Figure 4B .
Tumor area is demarcated with a white line. Closer examination reveals astrocytes found within stromal compartments (white arrow in high-magnification, merged image) and amongst the Olig2positive glioma cells (blue arrow) ( Fig 4B) .
After irradiation, Olig2-positive cells decrease to nearly undetectable levels; however, GFAP staining is retained in areas of the likely original tumor volume ( Fig 4C, likely tumor volume bounded in white identified by GFAP staining). In the areas demarcated by strong GFAP staining (white borders), this results in an increased ratio of GFAP to Olig2 in irradiated brains compared to untreated brains ( Fig 4D) .
In addition to characterizing astrocytes in vivo, we sought to characterize the in vitro response of astrocytes to radiation. Because in vitro cultivation of primary astrocytes shifts them to a more reactive phenotype than seen in vivo, 42 we tested whether our primary cultured astrocytes underwent any features of reactive gliosis in culture. Astrocytes exposed to 10 Gy radiation developed the classic morphology of somatic hypertrophy ( Fig 4E) and expressed elevated levels of the reactive marker vimentin ( Fig 4F) . 42 Furthermore, irradiated astrocytes expressed increased levels of the soluble proteins IL-6 ( Fig 4G) and IL-8 ( Fig 4H) , a response that persisted for up to ten days, indicating a persistant response to the intial irradiation.
To further characterize the astrocytic response to radiation in culture, we performed RNA sequencing on primary astrocytes 24 h after receiving a dose of 0 Gy or 10 Gy radiation.
Unsurprisingly, radiation had a profound effect on astrocyte gene expression. RNA sequencing analysis revealed distinct gene expression patterns that differ between control and irradiated astrocytes ( Fig 4I) , including an upregulation of the reactive astrocyte marker GFAP (p=4.6E-16). Table 1 ), which has been previously reported. 43 Other notable changes to gene sets were those involved in DNA repair and cell cycle-related gene sets ( Supplementary Table 1 ). This fits with previous reports that astrocytes respond to radiation by undergoing reactive gliosis, a state in which they often become proliferative. These findings support the potential for astrocytes to survive irradiation and persist in the irradiated tumor volume where they might modify the microenvironment.
Analysis of gene set enrichment data revealed an atypical response to irradiation, including suppression of the p53 pathway (Supplementary
In addition to radiation response genes, a variety of gene sets involved in cancer were altered.
Notably, gene sets associated with glioblastoma plasticity and gliomagenesis by PDGFB were upregulated, as were gene sets associated with the epithelial to mesenchymal transition, doxorubicin resistance, metastasis, and relapse in other cancer types ( Supplementary Table 1 ).
Interestingly, a gene signature consisting of the 100 most upregulated genes in irradiated astrocytes as compared to controls was significantly associated with worse survival in GBM, based on analysis of The Cancer Genome Atlas (TCGA) GBM dataset 44 ( Fig 4J) .
Irradiated astrocytes secrete TGM2 in vitro and in vivo after irradiation
To identify which proteins in the extracellular matrix might be responsible for the increased stemness and radioresistance of cells cultured on ADMi, we performed mass LC-MS/MS analysis on ADMc and ADMi ( Fig 5A) . Supplementary Table 2 lists proteins that changed significantly in matrix from irradiated astrocytes (summarized graphically in Figure 5A ). While multiple proteins within the dataset provide promising leads in identifying a potential target within the ECM, we selected transglutaminase 2 (TGM2) for further inquiry. TGM2 is a multifunctional protein with transamidating, deamidation, and GTPase activity, as well as enzyme-independent scaffolding functions. 45 It cross-links fibronectin and has scaffolding functions with integrin β1, both of which are associated with radiation resistance and stemness, 46, 47 and has recently been proposed to promote neurogensis from neural stem cells in the adult brain. 48 Its inhibition improved survival in a glioma xenograft model 49 and it has been shown to be a prognostic indicator of shorter time to relapse after chemoradiotherapy. 50 We first confirmed increased expression of TGM2 in matrix from multiple batches of astrocytes from different individuals by western blot (Fig 5B) . We followed this by examining TGM2 expression in vivo in our genetic model of PDGFB-driven gliomagenesis ( Fig 4A) . Whole brain sections were stained for Olig2 (green), TGM2 (yellow), and GFAP (magenta) ( Fig 5C-D) .
Relative to non-tumor bearing brain tissue, TGM2 expression was elevated in tumors (white bounded area, Fig 5C) , was extensively expressed in the stromal compartment, and showed areas of co-staining with GFAP ( Fig 5C, example: blue arrow, merged high magnification image). In the tumors treated with 10 Gy radiation ( Fig 5D) TGM2 expression was retained in the likely original tumor volume and even increased, resulting in a greater percent area covered by TGM2 ( Fig 5E) and increased ratio of TGM2 to Olig2 ( Fig 5F) within the area of TGM2-positive staining compared to the non-irradiated brain. In the irradiated tumors, regions of TGM2 staining were also found in close association with GFAP-sitive astrocytes, often co-staining or showing astrocytes surrounding areas of intense TGM2-positivity ( Fig 5D, example: blue arrow, merged high magnification image).
Another notable expression pattern for TGM2 demonstrates that, like GFAP, TGM2 expression is elevated in areas of microvascular proliferation and is closely associated with the vasculature ( Fig   5G) . Comparable to our findings in mice, analysis of the Ivy Glioblastoma Atlas Project (IVY-GAP), which examines gene expression within specific histologically defined regions of the tumor, 51 reveals that TGM2 is highly elevated in areas of microvascular proliferation (Supplemental Figure 3 ).
Taken together, these data suggest that irradiation promotes increased expression of TGM2 from astrocytes, which may promote radiation resistance of glioma cells. Furthermore, because this high expression is retained even after the tumor bulk recedes, it potentially provides a radioprotective environment for a newly expanding tumor. We therefore returned to our in vitro experimental systems to determine if there was a functional relationship between TGM2 and stemness and radiation resistance of glioma cells.
Astrocyte-derived TGM2 promotes glioma stemness after irradiation
To determine whether TGM2 expression might be associated with glioma cell stemness or radiation resistance, we examined the effects of either purified TGM2 or TGM2 inhibitors on our in vitro model of glioma cell-astrocyte matrix interaction. We found that purified TGM2, when coated onto ADMc, could raise the SP of glioma cells near to that seen with glioma cells cultured on ADMi ( Fig 6A) . In contrast, inhibition of TGM2 with two different TGM2 inhibitors, GK921 ( Fig 6B) and dansylcadaverine (DC; Fig 6C) decreased the SP of glioma cells cultured on ADMi to the levels seen on ADMc. GK921 also decreased survival after irradiation of glioma cells cultured on ADMi to levels seen on ADMc, while not affecting glioma cells cultured on ADMc ( Fig 6D) . These data suggest that TGM2 contributes to the increased stemness and radiation resistance of glioma cells cultured on ADMi as compared to those cultured on ADMc.
In vivo, tumors treated with 10 Gy radiation showed increased expression of CD44 ( Fig 6 E-H) , a stem cell marker in glioma 52 and a marker of mesenchymal subtype GBM, which strongly colocalized with TGM2 ( Fig 6G-H) . Like TGM2, CD44 expression was retained in the likely original tumor volume after irradiation, even as the Olig2-positive tumor cells receded, as seen by increased expression relative to Olig2 ( Fig 6F) . These data provide evidence that TGM2 expression is associated with increased stemness in vivo, which is elevated after irradiation.
TGM2 is a potential therapeutic target in GBM
To further examine the effects of TGM2 inhibition, we used an ex vivo organotypic slice model of GBM. We initiated tumors in our Nestin-tv-a Ink4a/Arf -/mice by injection with RCAS-PDGFB and shp53, then sliced freshly-harvested brains from mice upon detection of brain tumor symptoms. These slices were cultured overnight, followed by treatment with either 0 μM or 5 μM of the TGM2 inhibitor GK921 for 72 h. Slices were fixed then cryosectioned, followed by immunofluorescent detection of Olig2 to determine the presence of tumor cells in the slices.
Treatment of the slices with the TGM2 inhibitor significantly decreased the percent of Olig2positive nuclei in the sections, in some cases reducing Olig2-positive cells to undetectable levels ( Fig 7A-C) .
In human glioma, TGM2 mRNA is elevated as tumor grade increases (Fig 7D) . Likewise, TGM2
mRNA is significantly increased in isocitrate dehydrogenase wild type (IDHwt) tumors (Fig 7E) , the most aggressive tumor classification under the 2016 WHO classification system of diffuse gliomas. 53 Elevated TGM2 correlates with shorter survival times in glioma ( Fig 7F) . Within IDHwt GBM, tumors with the top 10% of TGM2 mRNA expression have the shortest survival times ( Fig 7G) . These data suggest that TGM2 may be a viable target in GBM.
Based on our findings, we suggest a model in which radiation stimulates tumor-associated astrocytes to secrete TGM2, which then promotes stemness and survival of glioma cells, allowing recurrence of the tumor (Fig 7F) . Our findings suggest that inhibition of TGM2 signaling provides a potential new therapeutic target to sensitize glioma cells to radiotherapy and prevent recurrence ( Fig 7F) .
Discussion
GBM treatment options are extremely limited after tumor recurrence. As surgery can rarely eliminate all GBM cells, identifying and targeting pathways that support GBM cell survival after radiotherapy is essential to improving outcomes. Clinical findings indicate that a short course of radiotherapy over three weeks results in no clinically significant difference in outcomes when compared to a six-week course. 54, 55 One interpretation of these data in light of findings presented here, is that neuroprotective pathways may be initiated in the brain in response to radiation, to protect cells from further radiation-induced damage, and that GBM cells can take advantage of this altered microenvironment. While many studies have begun examining how the tumor microenvironment can promote radiation resistance and associated GBM stemness, 28, [56] [57] [58] [59] little study has been made of how the stromal cells themselves respond to treatment modalities. This is an important question, as findings presented here suggest that stromal cells may respond to radiation in ways which could prime the microenvironment for protection of glioma cells against further radiation insults.
This study provides a promising new strategy in GBM treatment by examining lasting changes to the tumor microenvironment made by stromal cells in response to radiotherapy, which might be supporting radiation resistance of GBM cells. In particular, we identify astrocytes as persisting within the original tumor volume after the tumor bulk is killed by radiation. Tumor-associated astrocytes react to the GBM microenvironment with an altered phenotype, 60 and were recently shown to promote glioma growth. 32, 61 We show here that astrocytes secrete TGM2 in response to radiation, which supports stemness and radiation resistance of GBM cells. Inhibition of TGM2 decreased survival of tumor cells in an ex vivo organotypic slice model of GBM, and was previously shown to increase survival in a glioma xenograft model. 49 Our findings suggest a new strategy for sensitizing GBM cells to radiotherapy by short-circuiting the normal brain's protective response to radiation.
Materials and Methods
Generation of Murine Gliomas
Gliomas were induced in Nestin-tv-a or Nestin-tv-a Ink4a/Arf -/mice by injecting indicated combinations of RCAS-PDGFB and RCAS-shp53-transfected DF-1 cells (ATCC) intracranially in the brain as previously described. 62 
Cell Lines and Cultures
PIGPC were isolated as previously described. 17 PenStrep, N2, B27, EGF, and FGF (HGC Medium) as previously described 64 . Cells were grown to subconfluence, dissociated with Accutase (StemPro, Cat #A11105) and grown either as neurospheres or monolayer on laminin-coated (BioLamina, Cat #LN521) plastic.
Immunofluorescence
Cryosections were fixed in 4% PFA followed by permeabilization in 0.3% Triton-x-100 and blocking in 1% BSA in PBS. Cryosections of organotypic slice cultures were fixed in 4% PFA followed by permeabilization in 0.1% Triton-x-100 and 0.1% sodium citrate. Sections were incubated overnight in 1% BSA in PBS with the following primary antibodies:
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Co-culture experiments
For co-culture experiments 100,000 (BEND3, HMC3 or PIGPC) or 50,000 (HBPV) cells were pretreated with or without 10 Gy radiation following 48h of co-culture with 100,000 PIGPC cells.
Co-culture of microglia, pericytes, endothelial, or astrocytes cells and PIGPC cells was performed in DMEM.
Irradiation of cells
Irradiated pericytes, microglia, endothelial cells, and astrocytes were pretreated with 10 Gy irradiation in a CellRad x-ray cell irradiator (Faxitron).
Side Population Assay
For SP, cells were resuspended at 1 x 10 6 cells/ml and incubated at 37 °C, 30 minutes with or without 10 µM Fumitremorgin C (FTC) (Sigma). Cells were incubated for a further 90 minutes 
Generation of Astrocyte Derived Matrix
A confluent monolayer of astrocytes was irradiated with 0 Gy or 10 Gy followed by 10 days of culture on 0.2% gelatin in astrocyte medium supplemented with 50 µg/ml L-ascorbic acid (Sigma).
After 10 days, plates were decellularized in 0.4 mM NH4OH (Fluka), 0.5% Triton X-100 in PBS with 1 mM CaCl2 and 0.5 mM MgCl2 at 37 °C, washed with PBS containing 1 mM CaCl2 and 0.5 mM MgCl2, then treated with 10 µg/ml DNAse I (Roche) for 1 h at 37 °C. Plates were washed and stored in PBS containing 1 mM CaCl2 and 0.5 mM MgCl2 at 4 °C.
Western Blot
After preparation of astrocyte derived matrix on 6-well plates as described above, matrix was scraped into 175 μl 4X Laemmli buffer (Bio-Rad, 161-0747) containing 150 mM DTT and boiled for 10 min. Equal volumes of lysate were separated on 7.5% polyacrylamide gels followed by transfer to PVDF membranes and blocking with 5% non-fat dry milk in PBS. TGM2
immunodetection was performed using antibody to TGM2 (ab2386, Abcam) followed by detection with HRP-conjugated anti-mouse secondary antibody (ThermoFisher, 31430) and ECL substrate (ThermoFisher, 34095). Blots were visualized on the LAS-3000 Imager (Fujifilm) and quantified using ImageJ.
Sample preparation of Cell Derived Matrix
Cell derived matrix was solubilized for LC-MS/MS analysis according to Naba et al. 65 Briefly, ECM was washed three times with PBS followed by solubilization in 8 M urea and 10 mM DTT, with agitation for 2 h at 37 °C. Iodoacetamide was added to a final concentration of 25 mM followed by incubation in dark for 30 min at room temperature. Samples were deglycosylated by diluting samples to 2 M urea with 100 mM ammonium bicarbonate (pH 8.0) followed by treatment with PNGaseF and incubation with agitation at 37 °C for 2 h. Samples were digested with Lys-C, 2 h at 37 °C with agitation, followed by trypsin digestion overnight with agitation at 37 °C and a second trypsin digestion the next morning, 2 h at 37 °C with agitation. Trypsin was inactivated by acidifying the sample with freshly prepared 50% trifluoro-acetic acid (TFA) to a pH < 2. Samples were centrifuged at 16,000 x g for 5 min at room temperature and supernatant was collected into low-binding tubes and stored at -20 °C. All reagents were mass spec grade. Samples were speedvac to dryness and kept at -20°C until analyzed on the LC-MS/MS system. Crystal Violet for 1 hr. Colonies were photographed on a LAS-3000 imaging system, then counted using Image J followed by visual confirmation (to reduce interference from background staining of matrix proteins).
Solid Phase Extraction with
LC-MS/MS analysis
Self-Renewal Assay
U3082 cells were cultured on ADMc or ADMi for 5 days in HGC Media. For primary spheres, cells were dissociated with Accutase then replated in 3 wells each of 6-well dishes at 300 cells/ml in 2 ml HGC Media and cultured until visible spheres formed, typically between 14 and 18 days.
Primary spheres were visualized and counted on a Zeiss AX10 inverted microscope, then dissociated with Accutase and re-plated as described above. Secondary spheres were photographed on a Zeiss AX10 inverted microscope and counted.
RNA Sequencing Analyses
Sequencing performed at the Center for Translational Genomics, Lund University and Clinical Genomics Lund, SciLifeLab, and National Genomics Infrastructure Stockholm Node, Science for Life Laboratory. Raw count data was imported and analyzed using R statistic language (version 3.3.2). Data was rlog-normalized and combat corrected for experimental batch using DESeq2 and sva packages, respectively. DESeq differential expression analysis was performed on non-normalized raw counts. Genes with Benjamini adjusted p-values of <0.05 were considered differentially expressed. All genes ranked according to DESeq statistic (positive associated with highly expressed in irradiated astrocytes) and gene set enrichment analysis (GSEA) 67 was applied using the c2.all.v6.0 curated gene sets (MsidDB;
broad.mit.edu/gsea/msigdb).
Patient cohort analysis
The R2: Genomics Analysis and Visualization Platform (http://r2.amc.nl) was used to examine the Glioblasoma-TCGA-540 dataset. 44 Astrocyte irradiation signature score was calculated using the z-score of the top 100 upregulated genes. Kaplan-Meier analysis using the scanning method was applied to the signature score using overall survival data and Bonferoni adjusted p-values of <0.05 was considered significant. Data from the Allen Institute for Brain Science IVY-GAP (available at http://glioblastoma.alleninstitute.org) were analyzed using the GlioVis data portal for visualization and analysis of brain tumor expression datasets. 51, 68 
Culture in Sodium Alginate
Human astrocytes or PIGPCs were dissociated and counted. The cells were centrifuged at 0.5 x g for 5 minutes and resuspended in sodium alginate (Aldrich chemistry) 4:5 with cell culture medium. The cells were then added dropwise in medium containing 0.1 M CaCl2, which leads to the formation of hydrogel beads. The beads were allowed to settle for ten minutes at 37 o C, 5%
CO2 and then the medium was changed to new AM or DMEM.
Organotypic Slice Culture
Tumor-bearing brains from Nestin-tv-a Ink4a/Arf -/mice injected with RCAS-PDGFB and shp53
were sacrificed upon detection of brain tumor symptoms. Freshly dissected brains were sliced into 300 μm slices using a 5100 mz vibrating blade tissue slicer (Campden Instruments Ltd. White arrow indicates locations of interaction between astrocytes and vasculature. 
